Girolami Antonio, Scandellari Raffaella, Zanon Ezio, Sartori Roberto, Girolami Bruno
Department of Medical and Surgical Sciences, University of Padua Medical School, via Ospedale 105, 35128, Padua, Italy.
J Thromb Thrombolysis. 2006 Jun;21(3):279-84. doi: 10.1007/s11239-006-6556-7.
All reported cases of non-catheter induced venous thrombosis in patients with hemophilia A or B have been carefully evaluated. A total of 27 cases were reported,12 patients with hemophilia A and 15 patients with hemophilia B. The age of patients varied between 9 and 67 years. There were 10 cases of deep vein thrombosis, 8 patients with pulmonary embolism accompanied or not by deep vein thrombosis, 5 cases of superficial vein thrombosis. In addition, there were 3 cases of thrombosis in unusual sites (1 retinal central vein thrombosis and 2 portal vein thrombosis). Finally, in one case, venous thrombosis was multiple. There was a fatality in a hemophilia B patient with pulmonary embolism. The most frequent risk or triggering factor in hemophilia A was the administration of Feiba or rFVIIa concentrates in patients with inhibitors. Surgery together with Prothrombin Complex concentrates was the most frequent cause in hemophilia B patients. Congenital associated prothrombotic risk factors were present in two patients. No or very few therapeutic procedures were initiated in these patients but for a suspension or reduction of concentrates infusion. In a few instances low molecular weight heparin was given for a few days. The frequent association of venous thrombosis with infusion of concentrates indicates the need for a careful evaluation of patients about to receive such therapy.
所有关于甲型或乙型血友病患者非导管所致静脉血栓形成的报告病例均已得到仔细评估。共报告了27例病例,其中12例为甲型血友病患者,15例为乙型血友病患者。患者年龄在9岁至67岁之间。有10例深静脉血栓形成,8例伴有或不伴有深静脉血栓形成的肺栓塞患者,5例浅静脉血栓形成。此外,有3例血栓形成于不寻常部位(1例视网膜中央静脉血栓形成和2例门静脉血栓形成)。最后,有1例患者静脉血栓形成是多发性的。1例乙型血友病合并肺栓塞患者死亡。甲型血友病最常见的风险或触发因素是在有抑制剂的患者中使用拜科奇或重组凝血因子VIIa浓缩剂。手术联合凝血酶原复合物浓缩剂是乙型血友病患者最常见的病因。2例患者存在先天性相关血栓形成风险因素。这些患者未启动或仅启动了极少的治疗程序,只是暂停或减少了浓缩剂输注。在少数情况下,给予了几天的低分子量肝素。静脉血栓形成与浓缩剂输注频繁相关,这表明需要对即将接受此类治疗的患者进行仔细评估。